US 11,883,417 B2
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
Deng Pan, Chicago, IL (US); Masha Kocherginsky, Chicago, IL (US); and Suzanne D. Conzen, Park Ridge, IL (US)
Assigned to The University of Chicago, Chicago, IL (US)
Filed by The University of Chicago, Chicago, IL (US)
Filed on Jan. 18, 2022, as Appl. No. 17/577,882.
Application 17/577,882 is a continuation of application No. 16/596,342, filed on Oct. 8, 2019, granted, now 11,234,990.
Application 16/596,342 is a continuation of application No. 15/448,827, filed on Mar. 3, 2017, granted, now 10,441,596, issued on Apr. 18, 2017.
Application 15/448,827 is a continuation of application No. 14/296,127, filed on Jun. 4, 2014, granted, now 9,623,032, issued on Apr. 18, 2017.
Application 14/296,127 is a continuation of application No. 14/172,051, filed on Feb. 4, 2014, granted, now 9,149,485, issued on Oct. 6, 2015.
Application 14/172,051 is a continuation of application No. 13/071,363, filed on Mar. 24, 2011, granted, now 8,710,035, issued on Apr. 29, 2014.
Claims priority of provisional application 61/317,182, filed on Mar. 24, 2010.
Prior Publication US 2022/0133746 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/575 (2006.01); A61K 45/06 (2006.01); A61K 33/243 (2019.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/357 (2006.01); A61K 31/4745 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01); A61N 5/00 (2006.01); A61J 1/00 (2023.01); A61K 31/567 (2006.01); A61K 31/58 (2006.01)
CPC A61K 31/575 (2013.01) [A61J 1/00 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/357 (2013.01); A61K 31/4745 (2013.01); A61K 31/567 (2013.01); A61K 31/58 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61N 5/00 (2013.01)] 20 Claims
 
1. A method for treating breast cancer in a patient having breast cancer cells, the method comprising:
a) administering an effective amount of a glucocorticoid receptor antagonist to said patient, wherein said glucocorticoid receptor antagonist is selected from beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mifepristone, mometasone, triamcinolone, ORG-34517 (Merck), RU-43044, dexamethasone mesylate (Dex-Mes), dexamethasone oxetanone (Dex-Ox), deoxycorticosterone (DOC), CORT 0113083, and CORT 00112716, and wherein the patient expresses a detectable level of glucocorticoid receptor (GR) prior to administration of the GR antagonist;
b) then administering an effective amount of radiation, immunotherapy, or at least one chemotherapeutic agent.